江苏省拥有较为完备的产业体系，各类产业链条完整且协同性强，基础设施建设完善，成为企业发展沃 土。江苏省委书记信长星表示，江苏将致力于为广大外资企业在苏发展提供长期的稳定性和确定性，与 全球合作伙伴共享良好的创新生态、广阔的市场空间、完备的产业配套、充足的要素保障、畅达的交通 物流，携手推动产业链供应链合作向更高水平迈进。 11月18日至19日，2025年产业链供应链国际合作交流会暨企业家太湖论坛在江苏省无锡市举办。 作为江苏省人民政府重点打造的与跨国公司高水平对话合作的高层级平台，此次论坛聚焦"汇聚新质生 产力 开放合作赢未来"，现场设置了产业链对接展区、成果展示区等多个功能区域，通过实物展出、视 频介绍、现场讲解等形式，集中展示无锡在新能源、生物医药等领域的技术突破与合作成果。 商务部党组成员、部长助理袁晓明说："我们愿与各方分享中国超大规模市场红利，为全球产业链供应 链稳定运行提供重要支撑，为外资企业深耕中国提供优质土壤。" ...

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, with Changlian Co. contributing 30 million yuan, which represents 60% of the new company's registered capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]

Group 1 - The 21st Guangxi-Taiwan Economic and Cultural Cooperation Forum opened in Nanning, Guangxi, focusing on "New Opportunities in the Shared AI Era and Promoting New Development in Guangxi-Taiwan Cooperation" [1][2] - Key leaders emphasized the importance of seizing historical trends and opportunities for industrial cooperation and integration, aiming to expand international markets and strengthen the economy of the Chinese nation [1][2] - Guangxi is positioned as a favorable location for collaboration, with multiple advantages in terms of location and policy, encouraging entrepreneurs from both sides to explore business opportunities [1][2] Group 2 - Guangxi is experiencing its best historical development period, with a call for collaboration in the AI sector and the establishment of an AI application cooperation center between China and ASEAN countries [2] - The forum aims to deepen industrial cooperation and promote the integration of supply chains between Guangxi and Taiwan, enhancing cultural, tourism, education, and youth exchanges [2] - The event included discussions on AI industry development, youth innovation and entrepreneurship, and cultural exchanges, with sub-forums focusing on AI industry innovation and biomedicine [3]

新华社南宁11月11日电（记者赵欢）第二十一届桂台经贸文化合作论坛11日在广西南宁举行。论坛 以"共享AI时代新机遇，推进桂台合作新发展"为主题，与会两岸嘉宾期待以人工智能为新契机，深化经 贸文化合作，携手拓展东盟市场，共促融合发展。 本届论坛由国务院台湾事务办公室和广西壮族自治区人民政府共同主办。来自两岸的政商界人士、 科技企业代表、青年创业者及相关机构负责人出席活动。与会嘉宾围绕中国—东盟国家人工智能应用合 作中心建设等议题，探讨桂台人工智能产业赋能与行业场景应用融合发展，共商经贸文化交流新路径。 中共中央台办、国务院台办副主任潘贤掌说，本届论坛聚焦两岸人工智能合作，紧扣时代脉搏、呼 应发展热点，对持续深化两岸融合发展具有积极意义。"十五五"时期，中国式现代化建设将迎来崭新局 面，也将为台湾同胞实现人生出彩开辟更广阔空间。广大台胞台企应把握时代机遇，积极拥抱大陆市 场，从两岸融合发展中获得更多机遇与实惠。 中国国民党前代理主席林政则表示，人工智能已成为国际科技竞争的重要领域。大陆正加快布局前 沿研究与人才培养，广西依托良好生态和政策优势，正以人工智能为突破口推动产业转型与区域合作。 希望两岸企业把握人工智 ...

Core Insights - Fudan University has received approval to establish the Hongqiao Medical Innovation Park, which is expected to be completed around 2030, located in the Hongqiao International Central Business District [1] - The park will serve as a comprehensive innovation hub integrating education, research, industry, and services, aiming to align with world-class medical centers and enhance the integration of medical and industrial resources [1][2] Group 1 - The Hongqiao Medical Innovation Park will consist of five plots and is strategically positioned within the core area of the Hongqiao International Open Hub [1] - The park aims to create an integrated experimental zone for medical education and technology talent, a full-chain gathering area for the biopharmaceutical industry, and high-level international medical services [1][2] Group 2 - The establishment of the park is not merely an expansion of space but a strategic move to position Fudan University as a leader in new medical disciplines and interdisciplinary integration [2] - The park will focus on cutting-edge fields such as biomedicine, artificial intelligence, and biomedical engineering, facilitating seamless connections between basic research, clinical transformation, and industrial application [2] Group 3 - The park will leverage Fudan University's multidisciplinary strengths to advance in emerging fields like intelligent medicine and brain-machine interfaces, while also expanding into areas such as genetic medicine, cell and gene therapy, and vaccine safety [3]

Group 1: Core Insights - The "2025 IPEM Private Equity and Industry Conference" highlighted the significance of cross-border capital flow and industrial collaboration as key drivers of economic growth, particularly in the Asian market, with China showcasing immense investment potential and strategic value [1] - Technology investment is viewed as the core engine for global industrial transformation, with intense competition in innovation primarily concentrated in the US and China, especially in fields like commercial space, embodied intelligence, and artificial intelligence [1][2] Group 2: Regional Insights - Europe is recognized for its unique advantages in talent pool, company valuations, and vertical innovation, with increasing unicorns and rising annual financing in the tech market, particularly in AI, deep tech, and green technology [2] - The shift in cross-border investment dynamics is moving from unilateral inflow to multi-polar collaboration, emphasizing the importance of local partnerships and shared profitability for successful globalization [2] Group 3: Supply Chain Advantages - China's supply chain resilience, efficiency, and innovation are becoming central attractions for global capital, particularly in the biopharmaceutical sector, which has integrated deeply into the global supply chain over the past decade [3] - The dual-track policy in China for innovative drug development significantly reduces trial and error costs, positioning China as a global testing ground for pharmaceutical innovation [3] - The upgrade of China's supply chain advantages from cost-driven to technology-driven is evident, with hardware companies rapidly iterating products and forming a comprehensive advantage in sectors like electric vehicles and consumer electronics [3]

Core Viewpoint - The 2025 Shanghai International Biopharmaceutical Industry Week, themed "Linking the World, Empowering Industries," aims to foster innovation and collaboration in the biopharmaceutical sector, showcasing Shanghai's supportive ecosystem for drug and medical device development [1] Group 1: Ecosystem and Investment - The investment summit highlighted the importance of a robust innovation ecosystem, with Tsinghua University professor Hong Bo discussing brain-computer interfaces and their potential market impact, supported by significant funding from Shanghai state-owned capital [2] - The collaboration between academia and industry in Shanghai is crucial for the development of cutting-edge technologies, such as brain-computer interfaces, which require a steady supply of talent and resources [2] Group 2: Scientific Advancements - HIF (hypoxia-inducible factor) research is emerging as a critical area in cancer treatment, with Nobel laureate Greg Semenza presenting promising dual inhibitors targeting HIF-1α and HIF-2α, indicating Shanghai's potential as a hub for groundbreaking drug development [3] - Innovative projects from Shanghai universities, such as the development of allogeneic CAR-T cells, are progressing towards commercialization, demonstrating the city's capacity for translating academic research into viable products [4][5] Group 3: Policy Support and Market Access - Shanghai's "New and Excellent Drugs and Medical Devices" policy has accelerated the process for innovative products to enter hospitals, significantly reducing the time required for new drugs to be adopted in clinical settings [6] - As of August this year, 196 products have been included in Shanghai's "New and Excellent Drugs and Medical Devices" directory, reflecting the city's commitment to enhancing its biopharmaceutical innovation capabilities [6]

Core Insights - The 2025 Shanghai International Biopharmaceutical Industry Week, themed "Linking the World, Empowering Industries," is taking place from October 13 to 17, featuring various events aimed at fostering innovation and collaboration in the biopharmaceutical sector [1] Group 1: Innovation Ecosystem - Shanghai is recognized for its world-class innovation ecosystem and policy environment that supports the development of innovative drugs and medical devices, attracting investment and talent [1] - The city has been reducing the comprehensive costs of innovation and entrepreneurship in biopharmaceuticals during the 14th Five-Year Plan, facilitating faster drug screening and clinical research processes [1] Group 2: Investment and Financing - The investment summit highlighted the significance of brain-computer interface technology, with Shanghai Guotou's subsidiary leading a 100 million yuan investment in the company Borui Kang, which is developing a potential first-in-class brain-computer interface product [2] - The support from state-owned capital and the innovative ecosystem in Shanghai are crucial for the development of the brain-computer interface industry, which requires patient capital and a skilled workforce [2] Group 3: Cutting-edge Research - Research on HIF (hypoxia-inducible factor) as a target for cancer treatment is gaining traction, with Nobel laureate Greg Semenza presenting promising preclinical results on dual inhibitors targeting HIF-1α and HIF-2α [3] - Shanghai's strong academic institutions and collaboration between research teams and the industry position the city as a potential leader in groundbreaking drug development [3] Group 4: Innovative Projects - The development of allogeneic CAR-T cells by a team from East China Normal University represents a significant innovation, aiming to reduce the high costs associated with current autologous CAR-T therapies [4][5] - The project has received substantial funding from Shanghai Zhangjiang and is advancing towards commercialization with a focus on gene editing and cell therapy [5] Group 5: Policy Support - The introduction of the "New and Excellent Drugs and Medical Devices" policy in Shanghai has accelerated the process for innovative products to enter hospitals, significantly reducing the time required for new drugs to be adopted [6] - As of August this year, 196 products have been included in the "New and Excellent Drugs and Medical Devices" directory, reflecting the city's commitment to enhancing its biopharmaceutical innovation capabilities [6]

Group 1 - The "Million Talents Gathering in Nanyue" 2025 N City Linked Autumn Recruitment event commenced in Dalian, Liaoning, from October 15 to 18, organized by Zhongshan [1] - The recruitment event will cover four key universities in Liaoning, offering over 22,000 job positions, including more than 1,700 positions with annual salaries exceeding 200,000 yuan and over 220 positions with salaries above 500,000 yuan [1] - The job offerings align well with the academic strengths of Liaoning universities and the needs of Guangdong's modern industrial clusters, particularly in emerging industries such as new energy, artificial intelligence, new materials, and information technology [1] Group 2 - Over 790 enterprises and institutions registered for the recruitment event, providing more than 22,000 job positions, including over 17,000 for undergraduates, more than 1,900 for master's degree holders, and over 1,500 for doctoral candidates [2] - The recruitment features leading companies and innovative enterprises such as Mingyang Smart Energy, Kangfang Biotech, and Dayang Electric, as well as universities and research institutions, ensuring comprehensive coverage of industry and research [2]

Core Viewpoint - The article discusses the recent financial performance of a leading company in the technology sector, highlighting significant revenue growth and strategic initiatives aimed at expanding market share [1] Group 1: Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching $5 billion in the last quarter [1] - Net income rose to $1.2 billion, reflecting a 30% increase compared to the previous year [1] - The gross margin improved to 45%, up from 40% in the same quarter last year [1] Group 2: Strategic Initiatives - The company plans to invest $500 million in research and development to enhance product offerings and innovation [1] - A new partnership with a leading cloud service provider is expected to drive additional revenue streams [1] - The company aims to expand its presence in emerging markets, targeting a 15% growth in these regions over the next two years [1]